In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celgene invests in Quanticel; holds purchase option; option exercised

Executive Summary

Celgene Corp. has entered into an exclusive agreement with genomics start-up Quanticel Pharmaceuticals Inc. Celgene committed $45mm in funding during the initial three-and-a-half-year alliance term, took an undisclosed equity stake, and retains an exclusive option to both extend the deal and/or acquire the company.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register